Chongqing Huabo Pharmaceutical Group Co., Ltd.

Chongqing Huabo Pharmaceutical Group Co., Ltd. is a pharmaceutical wholesale enterprise mainly engaged in the agency of pharmaceutical products and the development of chain pharmacies, while also integrating trade, scientific research, market promotion, and medical services. Founded in April 2002, the company is a joint-stock enterprise established on the basis of Chongqing Huabo Pharmaceutical Co., Ltd. in accordance with modern enterprise systems, and has been approved by the National Medical Products Administration as a secondary narcotic drug supply point. To date, only our company and Chongqing Pharmaceutical Co., Ltd. hold this qualification in the Chongqing region. Our company is also a standing council member of the Chongqing Pharmaceutical Industry Association; there are only five standing council members in the pharmaceutical distribution industry.
[Subsidiary Introduction] Chongqing Mingji Technology Joint-stock Co., Ltd.
　　Chongqing Mingji Technology Joint-stock Co., Ltd. was jointly invested and established by Chongqing Huabo Pharmaceutical Group Co., Ltd. and Chengdu Renwoxing Technology Co., Ltd. It builds a pharmaceutical e-commerce platform and offline experience center serving the public, and carries out services such as medical consultation, health information, health record management, and humanistic care, gradually forming a comprehensive health management and service platform.

　　The company plans to integrate existing product resources, medical institution resources, chain terminal pharmacies, and distribution networks to develop targeted, differentiated B2B and B2C platforms, achieving seamless linkage of information flow, logistics, and capital flow within the region; secondly, following the advancement of national policies and the expansion of target customers, it will establish a drug supply chain network, physician and pharmacist service network, target consumer group network, and offline logistics and service undertaking system extending to major provincial capitals and county-level units nationwide, thereby realizing nationwide target group operations centered on the e-commerce platform and building an O2O platform; finally, extending from drug supply and services to deeper health services for target groups, ultimately building the platform into a comprehensive health platform integrating health services and supply chain integration, upgrading from a product supplier to an integrated solution provider for health services, and obtaining sustained platform profits from supply chain finance, value-added services, and big data marketing.
[Subsidiary Introduction] Brief Introduction of Chongqing Huabo Junwei Pharmaceutical Joint-stock Co., Ltd.
　　Since its establishment in 2012, Chongqing Huabo Junwei Pharmaceutical Joint-stock Co., Ltd. has always adhered to the business purpose of serving health, upholding a work style of sincerity, dedication, pragmatism, and efficiency. In recent years, it has developed into a military-civilian integration pharmaceutical wholesale enterprise with medical support and regional drug distribution as its core business, integrating the expansion of a comprehensive health industry center, pharmaceutical e-commerce, and third-party pharmaceutical logistics. It has a certain operating scale, good market reputation, and sustainable development in its market segments.
　　The company's warehouse area is over 3,000 square meters, with more than 4,000 drug specifications in operation. It has established stable business partnerships with more than 200 domestic pharmaceutical production and distribution enterprises. The company's main customers are hospitals, pharmaceutical commercial units, pharmacy terminals in Chongqing, as well as logistics procurement units of the People's Liberation Army and Armed Police Force, giving its sales network significant value. The company has more than 60 employees, of whom 63% have a college degree or above. It is equipped with refrigerated drug trucks and dedicated drug transport vehicles, strictly operates in accordance with GSP standards, and has achieved quality control and full-process traceability in all aspects of drug circulation.
　　In the next three years, Huabo Junwei will combine the reform of the medical and health system and the development trends of the pharmaceutical industry, adopt independent development and multi-party cooperation, build a third-party pharmaceutical logistics center and pharmaceutical e-commerce platform, extend medical support product research and development and health services, and build an integrated business format of research, production, distribution, and service, achieving leapfrog development.